On 7 March, EPAD has reached a new milestone when the EPAD Longitudinal Cohort Study (LCS) screened its 1.500 research participant in Bristol (UK). The largest ever public-private partnership in Alzheimer’s disease research, EPAD combines knowledge and expertise from 39 organisations across multiple sectors from academia and industry, bringing together a wealth of experience to its activities. By setting up a trial-ready cohort of research participants, creating a pan-European network of trial sites, developing a platform on which new compounds can be tested in a streamlined and efficient way, EPAD aims to accelerate the development of effective therapies.
Currently, EPAD has 21 study sites up and running across Europe and is adding new participants to the cohort every week. The consortium is now preparing the negotiations with the first intervention owner. The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.